Health & Beauty

Poxel Posts Results for First Half 2016

Poxel SA reported its results for the first half of 2016 ended June 30.

"We have made significant progress in continuing to build out Imeglimin's product profile and scientifically differentiate its mechanism of action from other drugs, as evidenced by the new data presented and published this year," said Thomas Kuhn, CEO of Poxel. "Additionally, we have continued to advance Imeglimin's Phase 2b trial in Japan and have recruited approximately 300 patients who have been randomized into the trial. Japan is a key focus for Poxel and is an integral part of our business strategy. Japan represents the second largest single market for type 2 diabetes with approximately $4 billion in annual sales and growth of almost 20 percent annually. Asia, in broader terms, is considered the most important geographic location with regards to treating the diabetes pandemic in the future."

In a release on Septemeber 12, the Company reported that highlights for the first half of 2016 included:


-The Company achieved several important milestones in developing Imeglimin for the Asian market and has key upcoming events.

-The Imeglimin dose-ranging, randomized, double-blind, placebo-controlled Phase 2b study with approximately 300 naive and pre-treated Japanese patients is fully enrolled and patients have been randomized into 24 weeks of treatment. The primary endpoint of the trial is efficacy measured by change in glycated haemoglobin A1c concentrations.

-The Japan Phase 2b Imeglimin results are anticipated during the second quarter of 2017.

-Poxel expects to be in the position to initiate the Phase 3 development program in Japan during the fourth quarter of 2017.

-Poxel has ongoing discussions with the European Medicines Agency (EMA) for the Phase 3 program in Europe as it finalizes its plan for this region. In addition, the Company remains engaged with the U.S. Food and Drug Administration and Japanese Pharmaceuticals and Medical Devices Agency as it prepares for the Phase 3 program in these countries.

-At the American Diabetes Association meeting in June 2016, Poxel presented compelling preclinical data showing Imeglimin's dual mechanism of action. Over the past year, the Company has made significant progress in understanding how Imeglimin improves both insulin sensitivity and secretion, which are the two key defects that cause type 2 diabetes. The new discovery that Imeglimin increases the nicotinamide adenine dinucleotide (NAD) synthesis, a pivotal molecule for mitochondrial function, further elucidates Imeglimin's unique mechanism of action on insulin secretion in response to glucose.

-In July, findings published in the American Journal of Physiology, Endocrinology and Metabolism demonstrate that Imeglimin primarily lowers glucose levels by increasing glucose-stimulated insulin secretion in a preclinical model. These findings highlight that Imeglimin's effect on insulin secretion in response to glucose is a direct effect as shown in isolated islets that act through amplification of mitochondrial metabolism-dependent signals. This data helps to explain the absence of hypoglycemia seen in clinical trials to date.

-At the upcoming European Association of Study for Diabetes (EASD) on September 14th in Munich, Poxel will present new preclinical results showing how Imeglimin improves vascular dysfunction in a type 2 diabetes animal model. Endothelium dysfunction is the first step in the development of cardiovascular diseases.


-PXL770 is a direct adenosine monophosphate-activated protein kinase (AMPK) activator, a key enzyme in energy metabolism acting as an energy sensor regulating glucose and lipid levels. AMPK activation is considered to mimic the effects of long-term exercise and plays an important role in diabetes management, especially for patients with cardiovascular risk factors.

-At the upcoming 2016 EASD meeting, Poxel will present new PXL770 data showing effect on de novo lipid synthesis and on weight and fat mass loss in an animal model of diabetes and obesity.

-PXL770 is in Phase 1 study in healthy volunteers. The single ascending dose trial enrolled 64 healthy male subjects to assess safety, tolerability and pharmacokinetics of six single ascending oral doses of PXL770. Poxel announced in June 2016 that results from the first part of the study indicate that PXL770 exhibits a favorable safety and tolerability profile with no serious adverse events reported or safety signal.

-During the Phase 1 study, Poxel observed a different metabolic pattern in humans compared to animals that were treated with PXL770. Therefore, based on regulatory guidelines, Poxel will need to further evaluate the profile of the metabolites, which may be pharmacologically active, prior to the start of the second part of the Phase 1 study. As a result of this additional preclinical work, the second part of the Phase 1b study will be delayed until 2017.


-In July 2016, Poxel closed a capital increase of 3,400,000 new ordinary shares for a total amount of EUR26.5 million. The Company expects that the net proceeds are sufficient to provide the Company with operating cash to early 2019, exclusive of any costs associated with funding a Phase 3 program for Imeglimin outside of Japan. The capital increase was subscribed for by prominent institutional investors in the United States and Europe.

-During the first quarter of 2016, the Company strengthened its Board of Directors with the addition of Pierre Legault, who is a member of the Board of Directors of several U.S.-listed biotechnology companies, and Janice Bourque, Managing Director of Hercules Technology Growth Capital. Pierre was appointed as the new Chairman of Poxel's Board of Directors in April, former chair Thierry Hercend will continue to support Poxel as a member of the Board.

-In addition, Jonae Barnes, who is based in Boston, joined the Company as Senior Vice President, Investor Relations and Public Relations. Jonae is working closely with Noah Beerman, Poxel's Executive Vice President, Business Development and President of U.S. Operations. Poxel intends to continue to expand in the United States from its Boston location, which is a global leading center in drug development and innovation. The Company also plans to expand its presence in Japan with additional hires to support the Phase 3 program in Japan together with Dr. Yohjiro Itoh, who is leading Poxel's clinical and regulatory operations in Asia.

((Comments on this story may be sent to


  • Alexandra Scarborough
    Papyrus Joins Forces with Designer Lela Rose

    Papyrus is looking to bring the “elegance and style” of fashion to its greeting cards via a new designer collaboration series.

    According to a release, the collaboration marks the first time a fashion design house and greeting card brand have joined forces to develop a custom greeting card collection.

    Papyrus said it is partnering with American fashion designer Lela Rose to introduce the series. Rose will feature her "sophisticated yet modern style" in the debut card and gift collection, slated to launch during New York Fashion Week. The collection will be available in New York City Papyrus stores and select retailers in September, with availability expanding to all Papyrus locations and retailers in October.

    "The fashion designer collaboration series is a celebration of the commitment Papyrus has to the arts, including a focus on the fashion industry, quality craftsmanship and trend-forward design," said Christy Kaprosy, President of Papyrus-Recycled Greetings. "We are delighted to have Lela Rose's elegant line lead the first Papyrus fashion designer collaboration program, and we are excited to bring more fashion designers to our loyal customers in the future."

    The company noted the collection, which draws inspiration from some of Rose's recent runway designs, consists of 16 cards and five gift accessories, including gift bags, gift tissue, roll wrap and a gift tag set. It also will be available online at

    "I'm thrilled to be the first designer to collaborate with Papyrus on their exclusive new fashion series," said Lela Rose. "This is a unique way to showcase our designs, silhouettes and prints, and extend the brand into a new category."



Ebola Philanthropy

Ebola Philanthropy

  1. Big Gift: Bill Gates, founder and co-chair of the Bill & Melinda Gates Foundation, has committed $50 million to fight the epidemic.
  2. Early Donation: In August, Paul G. Allen Family Foundation donated $2.8 million toward the outbreak in West Africa.
  3. Latest Pledge: Facebook founder Mark Zuckerberg and his wife Priscilla Chan this month pledged $25 million to the CDC.
  4. Corporate Funds: World Bank Group in August pledged up to US $200 million in emergency funding to help Guinea, Liberia, and Sierra Leone contain the spread of infections.
  5. Crowdfunding: Scripps Research Institute's Erica Ollman Saphire seeks to raise $100K for equipment to speed her work, partially funding by U.S. government.